Netherlands· NL-f959151944cb

Vipidia 25 mg filmomhulde tabletten

A alogliptin product containing alogliptinebenzoaat, registered in Netherlands by Takeda Pharma A/S. The same ATC class is registered in 13 of our 19 countries.

ATC A10BH04

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about alogliptinebenzoaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Alogliptin is registered in 13 of 19 countries.

Countries holding a registration under ATC A10BH04 (alogliptin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
6 of them publish a price we can compare per daily dose

Search alogliptin products by name

Alogliptin · ATC A10BH04

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Polandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of alogliptin costs, country by country.

Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Alogliptin · price per daily dose (25 mg)

USD · FX 28 Sept 2026

IT Italy$4.54

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: ALOGLIPTINEBENZOAAT
Manufacturer: Takeda Pharma A/S
Country: Netherlands (NL)
ATC code: A10BH04
ATC class: Alogliptin
Defined daily dose: 25 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/13/844

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

312 interactions on record for alogliptin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check alogliptin against other medicines How interaction checks work

Alogliptin · interactions on record

312 records

3 severe
269 moderate
40 minor

Most severe, free to view

GatifloxacinJ01MA16severe
SucralfateA02BX02moderate
ThiethylperazinA04AB03moderate
TriflupromazinA04AD06moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Alogliptin in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All alogliptin products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

Germany · Alogliptin Heumann
United Kingdom (Northern Ireland) · Alogliptin Aspire Pharma, Alogliptin Torrent
Iceland · Vipidia
Liechtenstein · Vipidia
Malta · Alogliptin Torrent
Norway · Vipidia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/f3367f7c-d06c-419f-a06b-8675688c461f
GET /v1/drugs/f3367f7c-d06c-419f-a06b-8675688c461f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vipidia-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Alogliptin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp112018",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MACROGOL 8000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "SCHELLAK (E 904)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "ALOGLIPTINEBENZOAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2013/09/19",
  "procedure_number": "EMEA/H/C/002182",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/844",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about alogliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console